Rachael Hough

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Sara Ghorashian, Anne Marijn Kramer, Shimobi Onuoha et al. · Nature Medicine · 2019 · 644 citations · Full text

Life Sciences, Immunology, Pediatrics +16

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 483 citations · Full text

Medicine, Hematology, Oncology +16

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pediatrics +13

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

Shaun Cordoba, Shimobi Onuoha, Simon Thomas et al. · Nature Medicine · 2021 · 272 citations · Full text

Medicine, Hematology, Oncology +17

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003

David O’Connor, Jessica Bate, Rachel Wade et al. · Blood · 2014 · 251 citations

Medicine, Infectious Diseases, Pediatrics +16